Characteristics of participants
| Disease area | RA/JIA/Still’s disease | SpA | PsA | All |
| N | 21 | 15 | 17 | 53 |
| Women, n (%) | 17 (81.0) | 7 (46.7) | 14 (82.4) | 38 (71.7) |
| Age (±SD) participants* Range of age in years | 28 (±4) 19–34 | 28 (±5) 21–35 | 28 (±5) 20–35 | 28 (±5) 19–35 |
| Disease duration in years (±SD)* Range of disease duration in years | 11 (±9) 1–28 | 6 (±5) 1–18 | 5 (±4) 1–15 | 8 (±7) 1–28 |
| Multimorbidity, n (%) | 6 (28.6) | 9 (60.0) | 7 (50.0) | 22 (41.5) |
| Current medication, n (%) | ||||
| cDMARDs | 14 (66.7) | 3 (20.0) | 7 (41.2) | 24 (45.3) |
| bDMARDs | 14 (66.7) | 6 (40.0) | 7 (41.2) | 27 (50.9) |
| tsDMARDs | 0 | 0 | 1 (5.9) | 1 (1.9) |
| Corticosteroids | 9 (42.9) | 1 (6.7) | 1 (5.9) | 11 (20.8) |
| NSAIDs | 8 (38.1) | 7 (46.7) | 5 (29.4) | 20 (37.7) |
| Educational level, n (%) | ||||
| Lower and/or upper secondary education (ISCED levels 2 and 3) | 4 (19.0) | 4 (26.7) | 4 (23.5) | 12 (22.6) |
| Post-secondary non-tertiary education and short-cycle tertiary education (ISCED levels 4 and 5) | 3 (14.3) | 3 (20.0) | 4 (23.5) | 10 (18.9) |
| Bachelor’s, Master’s, Doctoral or equivalent levels (ISCED levels 6, 7, 8) | 14 (66.7) | 8 (53.3) | 9 (52.9) | 31 (58.5) |
| Employment status, n (%) | ||||
| Full-time (30 hours or more) per week | 9 (42.9) | 8 (53.3) | 7 (41.2) | 24 (45.3) |
| Part-time up to 30 hours per week | 3 (14.3) | 3 (20.0) | 4 (23.5) | 10 (18.9) |
| Education/internship/student | 5 (23.8) | 4 (26.7) | 5 (29.4) | 14 (26.4) |
| Unemployed | 4 (19.0) | 1 (6.7) | 1 (5.9) | 6 (11.3) |
| Maternity leave/sabbatical | 0 | 0 | 1 (5.9) | 1 (1.9) |
| Self-reported activity level compared with other people of the same age, n (%) | ||||
| Physically more active | 4 (19.0) | 4 (26.7) | 3 (17.6) | 11 (20.8) |
| About as active | 7 (33.3) | 5 (33.3) | 10 (58.8) | 22 (41.5) |
| Less active | 10 (47.6) | 6 (40.0) | 4 (23.5) | 20 (37.7) |
N total number of participants.
n (%) number of participants (percentage).
*Age (±SD), mean age (SD).
bDMARDs, biological disease-modifying anti-rheumatic drugs; cDMARDs, conventional disease-modifying anti-rheumatic drugs; ISCED, International Standard Classification of Education; JIA, juvenile idiopathic arthritis; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis; tsDMARDs, targeted synthetic disease-modifying anti-rheumatic drugs.